Mild depressive symptoms are associated with gait impairment in early Parkinson's disease

Movement Disorders

Volumn 28, Issue 5, 2013, Pages 634-639

  Lord, Sue ^a   Galna, Brook ^a   Coleman, Shirley ^b   Burn, David ^a   Rochester, Lynn ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Attention; Depression; Gait; Parkinson's disease

Indexed keywords

AGED; ARTICLE; COGNITION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GAIT DISORDER; GERIATRIC DEPRESSION SCALE; HUMAN; LINEAR SYSTEM; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; PARKINSON DISEASE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; UNIFIED PARKINSON DISEASE RATING SCALE; WALKING SPEED;

AGED; DEPRESSION; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PARKINSON DISEASE; PSYCHIATRIC STATUS RATING SCALES; SEVERITY OF ILLNESS INDEX;

EID: 84877923635     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25338     Document Type: Article

References (40)

1. Lyness J, Moonseong H, Datto C, et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Intern Med. 2006;44:496-504.
2. Brandler TC, Wang C, Oh-Park M, Holtzer R, Verghese J. Depressive symptoms and gait dysfunction in the elderly. Am J Geriatr Psychiatry. 2012;20:425-432.
3. Brown RG, Landau S, Hindle JV, et al. Depression and anxiety related subtypes in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2011;82:803-809.
4. Ishihara L, Brayne C. A systematic review of depression and mental illness preceding Parkinson's disease. Acta Neurol Scand. 2006;113:211-220.
5. Lemke M. Depressive symptoms in Parkinson's disease. Eur J Neurol. 2008;15(Suppl 1):21-25.
6. Aarlsand D, Påhlhagen S, Ballard C, Ehrt U, Svenningsson P. Depression in Parkinson disease-epidemiology, mechanisms and management. Nat Rev Neurol. 2011;8:35-47.
7. Zarow C, Lyness S, Mortimer J, Chui H. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch Neurol. 2003;60:337-341.
8. Braak H, DelTredici K, Rub U, deVos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003;24:197-211.
9. Bohnen N, Kaufer D, Hendrickson R, Constantine G, Mathis C, Moore R. Cortical cholinergic denervation is associated with depressive symptoms in Parkinson's disease and parkinsonian dementia. J Neurol Neurosurg Psychiatry. 2007;78:641-643.
10. Burn D, Landau S, Hindle J, et al. Parkinson's disease motor subtypes and mood. Mov Disord. 2012;2:379-386.
11. Nutt JG, Horak FB, Bloem BR. Milestones in gait, balance, and falling. Mov Disord. 2011;26:1166-1174.
12. Yogev-Seligmann G, Giladi N, et al. Dual tasking, gait rhythmicity, and Parkinson's disease: Which aspects are attention demanding. Eur J Neurosci. 2005;22:124-1256.
13. Rochester L, Nieuwboer A, Baker K, et al. Walking speed during single and dual tasks in Parkinson's disease: which characteristics are important? Mov Disord. 2008;23:2312-2318.
14. Lord S, Baker K, Nieuwboer A, Burn D, Rochester L. Gait variability in Parkinson's disease: an indicator of non-dopaminergic contributors to gait dysfunction? J Neurol. 2011;258:566-572.
15. Khoo T, Duncan G, Yarnall A, et al. The spectrum of non-motor symptoms in early Parkinson's disease. Neurology 2013;80:1-6.
16. Gibb WRG, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry. 1988;51:745-752.
17. Folstein m, Folstein S, McHugh P. Mini-mental state. A practical method for grading the congitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-198.
18. McKeith I, Dickson D, Lowe J, et al. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1863-1872.
19. Litvan I, Bhatia KP, Burn DJ, et al. SIC task force appraisal of clinical diagnostic criteria for parkinsonian disorders. Mov Disord. 2003;18:467-486.
20. Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25:2649-2653.
21. Huppert FA, Cabelli ST, Matthews FE. Brief cognitive assessment in a UK population sample-distributional properties and the relationship between the MMSE and an extended mental state examination. BMC Geriatr. 2005;5:7.
22. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: Critique and recommendations. Mov Disord. 2007;22:1077-1092.
23. Meara J, Mitchelmore E, Hobson P. Use of the GDS-15 geriatric depression scale as a screening instrument for depressive symptomatology in patients with Parkinson's disease and their carers in the community. Age Ageing. 1999;28:35-38.
24. Goetz CG, Tilley BC T, Shaftman SR, et al. Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;22:2129-2170.
25. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology. 1967;17:427-442.
26. Bilney B, Morris M, Webster K. Concurrent related validity of the GAITRite walkway system for quantification of the spatial and temporal parameters of gait. Gait Posture. 2003; 17:68-74.
27. Holtzer R, Verghese J, Xue X, Lipton RB. Cognitive processes related to gait velocity: results from the Einstein Aging Study. Neuropsychology. 2006;20:215-223.
28. Zigmond A, Snaith R. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-370.
29. Hajjar I, Yang F, Sorond F, et al. A novel aging phenotype of slow gait, impaired executive function, and depressive symptoms: relationship to blood pressure and other cardiovascular risks. J Gerontol A Biol Sci Med Sci. 2009;64A:994-1001.
30. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA. 2011;305:50-58.
31. Tudor-Locke C, Bassett DJ. How many steps/day are enough? Preliminary pedometer indices for public health. Sports Med. 2004;34:1-8.
32. Lord S, Godfrey A, Galna B, Burn D, Rochester L. Patterns of daily ambulatory activity are different in early Parkinson's disease compared with controls. 16th International Congress of Parkinson's Disease and Movement Disorders, Dublin, UK; 2012.
33. Haumaue N, Ogat A, Terado M, et al. Brain catecholamine alterations and pathological features with aging in Parkinson disease model rat Induced by Japanese encephalitis virus. Neurochem Res. 2006;31:1451-1455.
34. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci U S A. 2007;104:13804-13809.
35. Sara S. The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci. 2009;10:211-223.
36. Muller M, Bohnen N, Bhaumik A, et al. Striatal dopaminergic denervation and cardiac post-ganglionic sympathetic denervation correlate independently with gait velocity in Parkinson's disease. Neurology. 2011;76(Supp 4):A265.
37. Nutt J, Carter J, Sexton G. The dopamine transporter: Importance in Parkinson's disease. Ann Neurol. 2004;55:766-773.
38. Moreau C, Delval A, Defebvre L, et al. Methylphenidate for gait hypokinesia and freezing in patients with Parkinson's disease undergoing subthalamic stimulation: a multicentre, parallel, randomised, placebo-controlled trial. Lancet Neurol. 2012;11:589-596.
39. Devos D, Krystkowiak P, Clement F, et al. Improvement of gait by chronic, high doses of methylphenidate in patients with advanced Parkinson's disease. J Neurol Neurosurg Psychiatry. 2007;78:470-475.
40. Parkinson's disease: diagnosis and management in primary and secondary care. NICE clinical guideline no. 35; 2006. Available at: http://www.nice.org.uk/CG035.